3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Completed
11
Active not recruiting
5
Terminated
4
Recruiting
2
Unknown
1
Not yet recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Gynecologic
1
Conditions
Carcinoma, Non-Small-Cell Lung
5
Small Cell Lung Carcinoma
3
Cholangiocarcinoma
3
Lung Neoplasms
2
Liver Neoplasms
2
Carcinoma, Hepatocellular
2
Urinary Bladder Neoplasms
1
Respiratory Tract Neoplasms
1
Rare Tumour
1
Pancreatic Neoplasms
1
Pancoast Syndrome
1
Ovarian Neoplasms
1
Gallbladder Neoplasms
1
Biliary Tract Neoplasms
1
Adenocarcinoma Of Esophagus
1
Interventions
Paclitaxel
9
Carboplatin
8
Bevacizumab
8
fluzoparib
5
olaparib
3
Topotecan
3
Gemcitabine
3
liposomal doxorubicin
2
famitinib
2
apatinib
2
Oxaliplatin
2
Magnetic Resonance Spectroscopy
2
Indocyanine Green
2
Drug Therapy
2
Cisplatin
2
trametinib
1
senaparib
1
pembrolizumab
1
niraparib
1
montelukast
1
irinotecan sucrosofate
1
fludarabine
1
durvalumab
1
dalpiciclib
1
dabrafenib
1
ceralasertib
1
anlotinib
1
aldesleukin
1
Ultrasonography, Doppler
1
Therapeutics
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Not yet recruiting
×
Ovarian Neoplasms
×
durvalumab
×
Clear all
NCT06650709
2024-10-23
NEOCATS
British Columbia Cancer Agency
Phase 2
Not yet recruiting
40 enrolled